Epigenetic Research Tools, Oncohistone Mutants, and Chromatin Biochemistry Reagents for Cancer Biology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Histone H4/H4C5 epigenetic drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | Recombinant Histone H4.1 / H4C5 Protein Unmodified, >95% purity, E. coli expressed, Endotoxin <1EU/µg. Sequence Verified. |
View Histone H4 Products |
| Antigen (Modified) | Histone H4 PTM Variants (K20me1, K16Ac) Site-specific modifications, Mass Spec verified, Theoretical MW confirmed. |
View Histone H4 Products |
| Antigen (Mutant) | H4C5 Oncohistone Mutants Cancer-associated variants for resistance mechanism studies. Sequence Verified. |
View H4C5 Products |
| Gene Delivery | H4C5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in chromatin studies. |
View H4C5 Products |
| Benchmark Ab | Anti-Histone H4 (Pan-specific) Recombinant rabbit monoclonal, ChIP-grade positive control. |
View Histone H4 Products |
| Validator | H4C5 siRNA Set For knockdown and nucleosome turnover verification. |
View H4C5 Products |
| Related Target: HDAC1 | Histone Deacetylase 1 Key enzyme acting on H4K16; synergistic epigenetic pathway. |
View HDAC1 Products |
| Related Target: H3F3A | Histone H3.3 Partner in nucleosome assembly; oncohistone hotspot (G34R/V). |
View H3F3A Products |
| Related Target: BRD4 | Bromodomain Containing Protein 4 Epigenetic reader recognizing acetylated H4. |
View BRD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nucleosome assembly requires stoichiometric purity and native folding | Recombinant H4C5 >95% purity (SDS-PAGE), Monodisperse (SEC), Refolded with H3 for octamer formation validated |
| PTM-specific antibody validation (cross-reactivity concerns) | Site-specific methylated (K20me1/2/3) and acetylated (K5/K8/K12/K16) proteins available; Mass spectrometry verified modifications |
| Oncohistone mechanistic studies (mutant vs WT) | Cancer-associated H4 variants available with Sequence Verified integrity for comparative biochemical assays |
| Epigenetic enzyme screening (HDAC/HAT substrates) | High-concentration stability at 1-2 mg/mL; Endotoxin controlled for sensitive primary cell assays |
Live Histone H4/H4C5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active HDAC Inhibitor Trials
- ➤ Latest Oncohistone Research
- ➤ Epigenetic Therapy Resistance Studies
- ➤ Recent Chromatin-Targeting Patents
Global Clinical Landscape & Future Outlook
The therapeutic landscape targeting histone biology is shifting from broad HDAC inhibitors toward selective epigenetic modulators, combination therapies with immune checkpoint inhibitors, and nucleosome-directed diagnostics. As liquid biopsy technologies mature, circulating nucleosomes containing specific Histone H4 modifications (particularly H4K20me3 and acetylated H4) are emerging as critical biomarkers for early cancer detection and treatment monitoring. The next wave of R&D focuses on targeted protein degradation (PROTACs) against epigenetic readers and writers, as well as applications in neurodegenerative diseases, requiring high-fidelity H4 substrates for mechanism-of-action studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| HDAC Inhibitor (Pan/Class I) | Novartis, Celgene (BMS) | CTCL, Multiple Myeloma | Acetylated H4 substrate for enzymatic assay (K16Ac/K12Ac specificity) |
| Bromodomain Inhibitor | OncoEthix (Merck), Resverlogix | AML, Solid Tumors | Acetylated H4 peptide/protein for binding assays (BRD4/H4 interaction) |
| Histone Methyltransferase Inhibitor | GSK, Pfizer | Sarcoma, Pediatric Brain | Methylated H4K20 substrates for PR-SET7/SET8 screening |
| Circulating Nucleosome Diagnostics | VOLITION, Roche | Colorectal, Lung Cancer | Highly specific anti-H4 PTM antibodies (validated against recombinant modified H4) |
| PROTACs / Degraders | Biotech Innovators | Refractory Cancers | High-fidelity H4 constructs for ternary complex formation assays |